{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:23:26Z","timestamp":1775604206816,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological regulation of blood pressure, and of heart and kidney functions. NPs have also been implicated in the pathogenesis of several cardiovascular diseases (CVDs), including hypertension, atherosclerosis, heart failure, and stroke. A fine comprehension of the molecular mechanisms dependent from NPs and underlying the promotion of cardiovascular damage has contributed to improve our understanding of the molecular basis of all major CVDs. Finally, the opportunity to target NPs in order to develop new therapeutic tools for a better treatment of CVDs has been developed over the years. The current Special Issue of the Journal covers all major aspects of the molecular implications of NPs in physiology and pathology of the cardiovascular system, including NP-based therapeutic approaches.<\/jats:p>","DOI":"10.3390\/ijms20163991","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T06:10:14Z","timestamp":1566195014000},"page":"3991","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics"],"prefix":"10.3390","volume":"20","author":[{"given":"Speranza","family":"Rubattu","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy"},{"name":"IRCCS Neuromed, 86077 Pozzilli (Isernia), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy"},{"name":"IRCCS Neuromed, 86077 Pozzilli (Isernia), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajh.2008.174","article-title":"Natriuretic peptides: An update on bioactivity, potential therapeutic use and implication in cardiovascular diseases","volume":"21","author":"Rubattu","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: Current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/187152509787047630","article-title":"Role of natriuretic peptide family in cardiovascular medicine","volume":"7","author":"Das","year":"2009","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40292-015-0112-5","article-title":"Angiotensin II receptor blocker nephrilysin inhibitor (ARNI): New avenues in cardiovascular therapy","volume":"22","author":"Volpe","year":"2015","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","article-title":"The Sacubitril\/Valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): Potential uses in hypertension, heart failure, and beyond","volume":"20","author":"Kario","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Forte, M., Madonna, M., Schiavon, S., Valenti, V., Versaci, F., Biondi Zoccai, G., Frati, G., and Sciarretta, S. (2019). Cardiovascular pleiotropic effects of atrial natriuretic peptide. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163874"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pandey, K.N. (2019). Genetic ablation and guanylyl cyclase\/natriuretic peptide receptor A: Impact on the pathophysiology of cardiovascular dysfunction. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163946"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20130427","article-title":"Atrial natriuretic peptide gene variants and circulating levels: Implications in cardiovascular diseases","volume":"127","author":"Rubattu","year":"2014","journal-title":"Clin. Sci. Lond"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tem.2007.11.006","article-title":"Control of lipolysis by natriuretic peptides and cyclic GMP","volume":"19","author":"Lafontan","year":"2008","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J. Clin. Invest."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bordicchia, M., Spannella, F., Ferretti, G., Bacchetti, T., Vignini, A., Di Pentima, C., Mazzanti, L., and Sarzani, R. (2019). PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020245"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2017.1305354","article-title":"Alirocumab for the treatment of hypercholesterolemia","volume":"17","author":"Tomlinson","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rubattu, S., Forte, M., Marchitti, S., and Volpe, M. (2019). Molecular implications of natriuretic peptides in the protection from hypertension and target organ damage development. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040798"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rubattu, S., Sciarretta, S., Marchitti, S., Bianchi, F., Forte, M., and Volpe, M. (2018). The T2238C atrial natriuretic peptide molecular variant and the risk of cardiovascular diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020540"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cannone, V., Scott, C.G., Decker, P.A., Larson, N.B., Palmas, W., Taylor, K.D., Wang, T.J., Gupta, D.K., Bielinski, S.J., and Burnett, J. (2017). A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189858"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jacc.2005.12.081","article-title":"Association of atrial natriuretic and type-A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension","volume":"48","author":"Rubattu","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199009133231114","article-title":"Increased human brain natriuretic peptide in congestive heart failure","volume":"323","author":"Mukoyama","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e12277","DOI":"10.1097\/MD.0000000000012277","article-title":"Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction","volume":"97","author":"Cui","year":"2018","journal-title":"Med. Baltim."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hfc.2017.08.002","article-title":"Natriuretic peptides in heart failure: Atrial and B-type natriuretic peptides","volume":"14","author":"Maisel","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ijcard.2013.04.164","article-title":"Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure","volume":"168","author":"Seronde","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs reduced ejection fraction in a prospective multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dorobantu, M., Mancia, G., Grassi, G., and Voicu, V. (2019). Natriuretic peptides. Hypertension and Heart Failure, Springer. Updates in Hypertension and Cardiovascular Protection.","DOI":"10.1007\/978-3-319-93320-7"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tanase, D.M., Rdu, S., Al Shurbaji, S., Baroi, G.L., Costea, C.L., Turliuc, M.D., Ouatu, A., and Floria, M. (2019). Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: From molecular evidences to clinical implications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112629"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15420\/cfr.2018.26.1","article-title":"Natriuretic peptides in chronic heart failure","volume":"5","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: Rationale and design of the PARAGON-HF trail","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jacc.2004.09.045","article-title":"Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation","volume":"45","author":"Ellinor","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Baba, M., Yoshida, K., and Ieda, M. (2019). Clinical application of natriuretic peptides in heart failure and atrial fibrillation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112824"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jchf.2013.02.004","article-title":"Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH Study (Biomarkers in Acute Heart Failure)","volume":"1","author":"Richards","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2005.05.057","article-title":"Impact of atrial fibrillation on the diagnostic performance of cardiac natriuretic peptide concentration in dyspneic patients: An analysis from the breathing not properly multinational study","volume":"46","author":"Knudsen","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","first-page":"1245","article-title":"Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm","volume":"20","author":"Fraser","year":"2004","journal-title":"Can. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/joa3.12111","article-title":"Multiple biomarkers and arrhythmia outcome following catheter ablation of atrial fibrillation: The Guangzhou Atrial Fibrillation Project","volume":"34","author":"Deng","year":"2018","journal-title":"J. Arrhytm."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Okamoto, R., Ali, Y., Hashizume, R., Suzuki, N., and Ito, M. (2019). BNP as a major player in the heart-kidney connection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143581"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e022776","DOI":"10.1136\/bmjopen-2018-022776","article-title":"Impact of renal dysfunction on the management and outcome of acute heart failure: Results from the French prospective, multicenter, DeFSSICA survey","volume":"9","author":"Fraticelli","year":"2019","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ejhf.468","article-title":"Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure","volume":"18","author":"McKie","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cao, Z., Jia, Y., and Zhu, B. (2019). BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081820"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1210\/en.2003-0128","article-title":"Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts","volume":"144","author":"Horio","year":"2003","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Moyes, A., and Hobbs, A. (2019). C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092281"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.116.08219","article-title":"Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity","volume":"69","author":"Nakao","year":"2017","journal-title":"Hypertension"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ejheart.2004.12.009","article-title":"C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity","volume":"7","author":"Passino","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"ref_46","first-page":"112","article-title":"New insights and new hope for pulmonary arterial hypertension","volume":"9","author":"Egom","year":"2017","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Egom, E.E.A. (2019). Pulmonary arterial hypertension due to NPR-C mutation: A novel paradigm for normal and pathologic remodeling?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123063"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cardiores.2006.08.012","article-title":"Intracellular peptides of natriuretic peptide receptor-C inhibit vascular hypertrophy via Gqa\/MAP kinase signaling pathways","volume":"72","author":"Li","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cannone, V., Cabassi, A., Volpi, R., and Burnett, J.C. (2019). Atrial natriuretic peptide: A molecular target of novel therapeutic approaches to cardio-metabolic disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133265"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Volpe, M., Rubattu, S., and Battistoni, A. (2019). ARNi: A novel approach to counteract cardiovascular diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092092"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/16\/3991\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:32Z","timestamp":1760188292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/16\/3991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":50,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["ijms20163991"],"URL":"https:\/\/doi.org\/10.3390\/ijms20163991","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]}}}